Welcome to MedTech Frontiers
A Monthly Event Hosted by Triple Ring Technologies
MedTech Frontiers is a continuing series of free events for medical device and life science investors, entrepreneurs, and technologists. Please join us for evenings of food, conversation, and presentations by Silicon Valley luminaries held on the first Thursday of each month.
Date: Thursday, September 4, 2014
Time: 6:00 pm - 9:00 pm
Triple Ring Technologies,
39655 Eureka Dr. Newark CA
Speaker: David Persing, MD, PhD
Cost: The seminar is free of charge, but advance registration is required
On-Site registration: A limited number of on-site registrations may be available
About the Seminar:In many clinical settings, the medical value of a diagnostic result is tied directly to how quickly it can be linked to patient management and/or treatment decisions. Despite notable advances in recent years, molecular diagnostics applications for infectious disease detection have yet to reach their full potential. Often performed in specialized laboratories far removed from where patient care decisions are made, specimens usually spend more time in transit than in actually being analyzed. Further, once samples do arrive in the lab, additional delays are incurred by batch processing. The chief limitations of current first-generation molecular diagnostics approaches are not due to the underlying technology, but rather in how this technology is implemented. Fortunately, next generation technologies for nucleic acid detection are now evolving in the direction of modern clinical chemistry analyzers, the most successful of which allow for random access, high throughput, and STAT testing capability. This presentation will focus on a case study of a next generation molecular diagnostic test that addresses the needs above, specifically surrounding tuberculosis and drug resistance. The Xpert MTB/Rif test accomplishes this in an easy to use diagnostic cartridge. Xpert MTB/Rif was endorsed by the WHO in 2010 and has now reached 108 countries worldwide.
About the Presenter:Dr. Persing first joined Cepheid as a director in May 2004 and became Executive Vice President and Chief Medical and Technology Officer in August 2005. From 1999 to 2005, Dr. Persing was Senior Vice President and Chief Scientific Officer at Corixa Corporation, a Seattle-based biotechnology company, until its acquisition by GlaxoSmithKline. Prior to that, he was a member of the Clinical and Research Faculty in the Department of Laboratory Medicine and Pathology at the Mayo Clinic in Rochester, Minnesota where he developed several extramurally funded infectious disease research programs. From 1992 to 1999, he established and directed the Mayo Molecular Microbiology Laboratory which was one of the first reference laboratories to offer cutting-edge molecular diagnostic testing on a worldwide basis. He has authored over 270 peer-reviewed articles including frequently cited papers in the New England Journal of Medicine, Science, and PNAS. He served as Editor in Chief for four leading textbooks on Molecular Diagnostics, the most recent of which was released in January 2011. Dr. Persing received his M.D. and Ph.D. (Genetics) degrees from the University of California, San Francisco in 1988 and completed his residency training in Clinical Pathology at the Yale School of Medicine in 1990.
Past Events Page for a listing of
Our monthly MedTech Frontiers gathering features a prominent thought-leader. Please join us. Click here for more information.
Triple Ring Technologies is currently looking for a few exceptionally talented individuals. For more information, click here.